Treatment with a pharmaceutical composition comprising manf2 nucleic acid

Abstract

A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.

What is claimed: 
     
         1 . A method of treating the symptoms of amyotrophic lateral sclerosis, ALS, in a patent in need thereof, the method comprising:
 directly administering to the central nervous system of the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof, wherein said functional fragment is capable of preventing the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons, and wherein said functional fragment comprises amino acids 27-187 of the amino acid sequence SEQ ID NO:2.   
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition comprises SEQ ID NO:2. 
     
     
         3 . The method of  claim 1 , wherein the functional fragment consists of amino acids 27-187 of the amino acid sequence of SEQ ID NO:2.